Biosecure Act Influences $323 Million Biologics Manufacturing Deal
Samsung Biologics disclosed a five-year, $323 million manufacturing agreement whose filing linked the client’s sourcing decision to the U.S. Biosecure Act. Although a private-sector transaction, it signals how federal restrictions may shape supplier choices for companies with government contracts or grants as agencies prepare further guidance.